Recommendations for treatment of lymphomatoid papulosis with methotrexate: a report from the Dutch Cutaneous Lymphoma Group

Evaluation of treatment results in multifocal primary cutaneous anaplastic large cell lymphoma: report of the Dutch Cutaneous Lymphoma Group

“…Four patients obtained a CR or PR (ORR 57%) during maintenance therapy with MTX, whereas three patients experienced insufficient effect. These data suggest that low‐dose MTX may be effective in multifocal C‐ALCL, although the response rate is lower than reported in LyP . Moreover, relapses are common and continued or repeated maintenance treatment is often required.…”

“…These data suggest that low-dose MTX may be effective in multifocal C-ALCL, although the response rate is lower than reported in LyP. 26,27 Moreover, relapses are common and continued or repeated maintenance treatment is often required. Apart from MTX, anecdotal case reports and small series suggest that etoposide, vinblastine and retinoids (bexarotene, acitretin and isotretinoin) alone, or in combination with interferon alpha may represent alternative effective and well-tolerated options for refractory multifocal C-ALCL.…”

“…2 Following our publication in 2000, CHOP was therefore no longer used for patients with only multifocal skin lesions and has been largely replaced by low-dose MTX. Low-dose MTX is effective in patients with LyP with response rates up to 93%, 26,27 and has been proposed as firstline therapy for multifocal C-ALCL. 2,5,10 However, evidence for this recommendation is scarce.…”

“…Low‐dose MTX is effective in patients with LyP with response rates up to 93%, and has been proposed as first‐line therapy for multifocal C‐ALCL . However, evidence for this recommendation is scarce.…”

Primär kutane CD30+ lymphoproliferative Erkrankungen

“…Allerdings konnten nur sechs Patienten erfolgreich von Methotrexat entwöhnt werden und es gibt keine Möglichkeit vorherzusagen, welche Patienten in der Lage sein werden, erfolgreich mit dem Behandlungsschema aufzuhören. Methotrexat wird daher nur bei Patienten empfohlen, die eine hohe Symptombelastung, wie ausgedehnte Hautbeteiligung, Ulzera, Narbenbildung, oder schweren Juckreiz aufweisen . Ein weiterer systemischer Behandlungsansatz ist Brentuximab Vedotin, ein monoklonaler Antikörper (cAC10), der an Monomethyl‐Auristatin E gebunden ist und an CD30‐Rezeptoren bindet.…”